Physician profile
Avegiyel E Dunn
NPI 1417224338
$2,749.43
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,347 · 2020: $373 · 2021: $12.77 · 2023: $16.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $659.01 | 2019-2020 | |
| Pfizer INC. | $232.50 | 2019-2020 | |
| Lilly USA, LLC | $229.59 | 2019-2020 | |
| Novo Nordisk INC | $216.92 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $203.01 | 2019-2020 | |
| Glaxosmithkline, LLC. | $146.66 | 2019-2020 | |
| Amarin Pharma, INC. | $137.18 | 2019-2020 | |
| Amgen INC. | $135.73 | 2019 | |
| Merck Sharp & Dohme LLC | $135.01 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.48 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $126.90 | 2019-2020 | |
| Allergan, INC. | $83.76 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $49.19 | 2019 | |
| Sanofi-Aventis U.S. LLC | $40.61 | 2019 | |
| Sunovion Pharmaceuticals INC. | $39.61 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $36.65 | 2019-2020 | |
| Abbvie INC. | $29.22 | 2021-2023 | Ubrelvy |
| Novartis Pharmaceuticals Corporation | $27.60 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.28 | 2019 | |
| Ironshore Pharmaceuticals INC. | $23.38 | 2019 | |
| Astellas Pharma US INC | $23.15 | 2019 | |
| Shire North American Group INC | $18.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avegiyel Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.